GANSU, China, May 18 /PRNewswire-Asia-FirstCall/ -- China Dasheng Biotechnology Company (“China Dasheng” or “the Company”) , a leading producer and distributor of organic bacteria based additives for crops and livestock feeds in the PRC, announced unaudited financial results for the third quarter of fiscal year 2009, which ended March 31, 2009.
Chairman of the Board, Mr. Jinjun Qi commented, “China Dasheng reported another successful quarter, demonstrating the power and continued strength of our core business offerings. There is a growing demand in China at both the national and local level for “going Green” agriculture and the Company is uniquely position to capitalize on this trend with our proprietary products and leading market position.
During the third quarter we posted solid year-over-year revenue growth all while continuing to deliver sustained and growing cash flows, enabling us to fund our future growth. We also had a very strong quarter from an expense management perspective, as we intensified our focus on those measures that would allow us to increase productivity and expand margins. It is clear that the financial disciplines we put in place are bearing fruit.”
About China Dasheng Biotechnology Company
China Dasheng Biotechnology Company, a leading producer and distributor of organic bacteria based additives for crops and livestock feeds through its three subsidiary segments, Gansu Dasheng Biotechnology Company, Hainan Lushen Biology Technology Company and Yangling Elemiss Foods Company, operates within the biological products and fertilizer agents market including organic fertilizers, non-chemical agents, and biological agents based additives. The major product line of AM/HM biological bacterial crop and live stock feed additive were certified by the China Green Product Development Center as a “Grade A Green Food Raw Material.” To learn more about the Company visit http://www.chinadashengbio.com .
Safe Harbor Statement
The statements contained herein that are not historical facts are “forward-looking statements” within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” or “anticipates” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors discussed herein and expressed from time to time in our filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward-looking statements are made only as of the date of this filing, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
CHINA DASHENG BIOTECHNOLOGY COMPANY (FORMERLY NAMED AS MAX NUTRITION INC.) CONSOLIDATED BALANCE SHEETS (Unaudited) AS OF MARCH 31, 2009 and JUNE 30, 2008
CHINA DASHENG BIOTECHNOLOGY COMPANY (FORMERLY NAMED AS MAX NUTRITION INC.) CONSOLIDATED STATEMENTS OF OPERATION (Unaudited) FOR THE NINE AND THREE MONTHS
CHINA DASHENG BIOTECHNOLOGY COMPANY (FORMERLY NAMED AS MAX NUTRITION INC.)
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) FOR THE NINE MONTHS ENDED
CONTACT: China Dasheng Biotechnology Company: James Gao, Vice President,
Investor Relations at +1-908-938-2025 or gaojingbo@chinadashengbio.com
Web site: http://www.chinadashengbio.com/
